To determine the role of DCs in RT combined with anti-TIGIT therapy, we first measured the expression of CD155 on DCs in TdLNs and non-TdLNs from a tumor mouse model and normal-LNs from healthy mice using flow cytometry. The gene discussed is TIGIT; the disease is neoplasm.